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Abstract 
 
Many chemotherapy agents are toxic to the heart, such that increasing numbers of cancer 
survivors are now living with the potentially lethal cardiovascular consequences of their 
treatment. Earlier and more sensitive detection of chemotherapy-induced cardiotoxicity 
may allow improved treatment strategies and increase long-term survival. Lipophilic cation 
positron emission tomography (PET) tracers may be suitable for early detection of 
cardiotoxicity. This study aims to evaluate an 18F-labelled lipophilic phosphonium cation 
e.g. 18F-Mitophos, as a cardiac imaging agent, comparing it to leading PET and SPECT 
lipophilic cationic tracers before further assessing its potential for imaging cardiotoxicity 
in an acute doxorubicin (DOX) model. 
 
Methods 
 
Cardiac uptake and response to decreased mitochondrial membrane potential (ΔΨm) of 18F-
Mitophos and 99mTc-Sestamibi were tested in isolated perfused rat hearts. Baseline 
pharmacokinetic profiles of 18F-Mitophos and 18F-FBnTP and their response to acute DOX-
induced cardiotoxicity were assessed in rats in vivo (10, 15 or 20 mg/kg DOX, i.v., 48 h 
prior).  
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Results 
 
Cardiac retention of 18F-Mitophos was over double that of 99mTc-Sestamibi in isolated 
perfused rat hearts. Favourable biodistribution of 18F-Mitophos in vivo was observed with 
heart to tissue ratios of 304  186, 11.2  1.2 and 3.8  0.6 for plasma, liver and lung 
respectively (60 min). A significant dose-dependent loss of cardiac retention of 18F-
Mitophos was observed upon DOX treatment where average cardiac SUV30-60 (mean  SD) 
decreased from 3.5  0.5 (control) to 1.8  0.1 (DOX 20 mg/kg). Other biomarkers assessed 
showed no alterations. 
 
Conclusions 
 
18F-Mitophos showed suitable pharmacokinetic parameters for cardiac imaging. A 
significant dose-response of cardiac uptake to DOX treatment was observed before 
detectable biomarker alterations. It is therefore, a promising tracer for imaging 
chemotherapy-induced cardiotoxicity. This is the first demonstration of PET radiolabelled 
lipophilic cations being used for the imaging of chemotherapy-induced cardiotoxicity 
imaging and indicates the potential application of these compounds in this area. 
 
Keywords: Phosphonium cations, 18F radiochemistry, PET, cardiotoxicity, doxorubicin 
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Introduction 
 
Long term cancer survival rates are increasing, with >5 year survival rate rising from 49% 
for diagnoses made in the mid-1970s, to 69% for diagnoses made in 2005-2011, in the 
United States.1 However, many cancer treatments are not themselves benign, and the long 
term effects of cancer treatment are increasingly impacting upon patient morbidity and 
mortality. Doxorubicin (DOX) is a widely used and effective anthracycline chemotherapy 
agent used in the treatment of a variety of cancers.2,3 Its therapeutic potential, however, is 
limited by severe and potentially lethal cardiotoxic effects. Approximately 10% of patients 
treated with DOX will develop potentially life threatening cardiotoxicity up to 10 years 
after treatment,4 with higher cumulative doses increasing risk dramatically.5 Of those who 
develop congestive heart failure, mortality is approximately 50%.6,7  
 
Cardiotoxicity is currently routinely monitored by echocardiography (echo) or MUGA 
scanning, typically defined by a greater than 10% reduction of left ventricle ejection 
fraction (LVEF).3,8 However, such loss of contractile function typically indicates 
significant irreversible myocardial injury, where opportunities to intervene or modify 
treatment are limited.3,9  
 
Measuring evolving cardiac damage at a sub-cellular level using a molecular imaging 
approach could provide earlier and more sensitive assessment of cardiotoxicity, however 
most approaches explored to date are limited in capacity or in a relatively early stage .10,11  
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‘Metabolism’ tracers such as 18F-FDG and 11C-acetate have been investigated, however, 
cardiac retention is heavily influenced by other parameters, such as dietary substrate 
availability, which complicate their use.12 Tracers more closely related to the mechanisms 
of cardiotoxicity such as 123I-MIBG, which is sensitive to sympathetic nervous system 
alterations, show greater promise and have shown response to DOX treatment pre-
clinically, and in patients.13 However, slow clearance from blood and significant liver 
uptake impact upon their clinical utility.14 
 
Although the exact mechanism of cardiotoxicity by DOX is not fully understood, 
mitochondrial dysfunction, directly or indirectly, is central to the proposed 
mechanisms.4,15,16 Fluorescent lipophilic cations such as the rhodamine or JC-1 dyes have 
been used to report on mitochondrial function in vitro for many years. They accumulate 
via passive diffusion through cell membranes of mitochondria according to the 
mitochondrial membrane potential (ΔΨm), with PET-labelled derivatives showing good 
sensitivity in myocardial infarction models.17 Our collaborators have recently 
demonstrated the potential for using radiolabelled lipophilic cations to report on 
doxorubicin-induced mitochondrial dysfunction with 99mTc-sestamibi for SPECT 
imaging.18 While proof of concept with SPECT imaging has been demonstrated, PET has 
significant advantages for this approach in terms of sensitivity and the capacity for 3-
dimensional pharmacokinetic analysis. 
 
This study therefore aims to evaluate our recently developed PET lipophilic cation 18F-
Mitophos19 as a cardiac imaging agent. We hypothesise that PET radiolabelled lipophilic 
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cations such as 18F-Mitophos, which are sensitive to ΔΨm alterations and accumulate in 
cardiac tissue, may allow early detection of DOX-induced cardiotoxicity, potentially 
before mechanical alterations in cardiac function manifest.  
 
Materials and Methods 
 
Animal Procedures 
All animal procedures were performed in accordance with the United Kingdom Home 
Office Animals (Scientific Procedures) Act 1986 and the EU directive 2010/63/EU. The 
procedures were reviewed by independent ethics committees (Imperial College London 
and King’s College London). All animals were sourced from Charles River.  
 
Radiopharmaceutical Preparation 
18F-Mitophos was produced in >99% radiochemical purity and molar activity of 24.6 ± 
18.3 GBq/μmol by a fully automated two-step radiosynthesis process, adapted from the 
previously reported methodology (Figure 1).20 18F-FBnTP was produced in >99% 
radiochemical purity and specific activity 15.0 ± 12.6 GBq/μmol in a fully automated 
four-step radiosynthesis, modified from literature (Figure 1).21 For further details please 
refer to Online Supplement. 99mTc-sestamibi was prepared from commercial cold kits 
(Mallinckrodt Pharmaceuticals) reconstituted with saline (100 MBq/mL) from a 
99Mo/99mTc generator and supplied by the radiopharmacy at St. Thomas’ Hospital, King’s 
College, London, UK. 
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Langendorff Heart Perfusion 
To investigate tracer response to decreased ΔΨm, uptake and kinetic modelling of 18F-
Mitophos was compared to that of SPECT lipophilic cardiac tracer 99mTc-Sestamibi in male 
Wistar rat hearts (n = 4-6 per group, 300-330 g) on a triple--detection Langendorff 
perfusion set-up, previously described.22,23 Tracers were compared under normoxic control 
perfusion and in hearts treated with the ΔΨm uncoupler carbonyl cyanide 3-
chlorophenylhydrazone (CCCP). Cardiac function of perfused hearts was monitored 
through measurements of left ventricular end-diastolic pressure (LVEDP) and left 
ventricular developed pressure (LVDP). Cardiac radiotracer uptake was recorded, decay 
corrected, and exponential washout component (K) was calculated from least squares fit of 
data from 2 min post injection.  
 
Ex vivo biodistribution 
Male Sprague Dawley rats (300-500 g; n = 3 per time-point) were anaesthetised and 18F-
Mitophos or 18F-FBnTP (5.1 ± 1.3 MBq) was administered intravenously (i.v.) Animals 
were culled at 5, 15, 30 or 60 min post administration and tissues were collected and 
radioactivity measured via gamma counter (Wizard).  
 
The distribution of radioactivity in tissue and plasma are expressed as mean standardised 
uptake values (SUV), where SUV = (%ID x BW)/100%ID is the percent of injected dose 
per gram of tissues and BW is the body weight of the animal (g). 
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Metabolite Analysis 
Blood samples were collected 5, 10, 20, 40 and 60 min post tracer administration (n = 3 
per timepoint). Proteins were precipitated from plasma with acetonitrile (ACN) (plasma: 
ACN ration 1:1) and centrifuged. HPLC analysis of supernatant allowed the parent fraction 
to be determined.  
 
Dynamic PET:CT cardiac scanning 
Animals were anaesthetised and venous and arterial angiocatheters were inserted for 
radiotracer injection and periodic blood sampling, respectively. A CT scan was conducted 
for attenuation correction before injection of radiotracer and dynamic PET data acquired 
(60 min). Selected regions of interest were drawn over the heart and used to generate the 
time activity curves (TACs).  
 
In vivo intra-animal variability 
Sprague Dawley rats (n = 4, 408 ± 95 g) underwent 60 min dynamic PET-CT scans with 
injection of 18F-Mitophos (6.2 ± 2.0 MBq). After 48 h, animals were scanned a second time 
with 18F-Mitophos (7.2 ± 1.2 MBq). Cardiac SUV30-60 was determined from dynamic scan 
TAC of the left ventricle and was used to calculate variability. 
 
Acute in vivo DOX cardiotoxicity model 
Sprague Dawley rats underwent slow continuous i.v. infusion of DOX (10, 15 or 20 mg/kg) 
over 1 h. Rats were monitored for signs of adverse effects over a 48 h period. 48 h post 
DOX infusion, rats were placed under terminal anaesthesia and 18F-Mitophos (6.3 ± 1.7 
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MBq) was injected i.v. A subset of rats (n = 3 and n = 4 for the 15 mg/kg and 20 mg/kg 
groups, respectively) underwent dynamic PET-CT scans with TAC generation over left 
ventricle. Target tissue activity was measured with a gamma counter 60 min post injection; 
cardiac tissue and blood plasma were frozen for further analysis. 
 
Cardiotoxicity biomarker analysis 
Plasma collected at the end of the protocol was analysed for cardiac troponin-I levels 
(Ultra-sensitive rat cardiac troponin-I ELISA, Life diagnostics, UK). Samples were thawed 
to ambient temperature and ELISA carried out as per the manufacturer’s instructions, with 
adaptations of the standard curve to increase sensitivity for lower doses. Standard curve 
from 19.5 pg/mL to 625 pg/mL rat cardiac troponin-I was used for quantification (R2 
>0.999). 
 
Levels of malondialdehyde (MDA) were evaluated in cardiac muscle tissue as a biomarker 
of oxidative stress. MDA was extracted from left ventricle tissue as previously described.24 
Each sample was transferred to a 96 well plate for reading and measured in triplicate 
(absorbance, 586 nm). A standard curve from 1.25 to 40 nmol/mL MDA was used for 
quantification (R2 >0.999). 
 
Histological assessment of cardiac tissue from DOX treated rats was carried out on 
longitudinal sections of ventricle via H&E staining. Fresh-frozen cardiac tissue was 
sectioned (10 m) using a cryostat and thaw-mounted onto superfrost slides. Staining was 
carried out by fixing the tissue with Clarkes solution (3:1 v/v EtOH: glacial acetic acid). 
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Slides were incubated with haematoxylin solution, differentiated in 1% HCl, before 
submerging in eosin solution (aq. 1%). Tissue was then dehydrated in EtOH (85%, 100%, 
100%), cleared in xylene and allowed to dry prior to the application of DPX medium. 
Myocardial damage (n = 3 sections per heart, n = 4 hearts per group) was assessed by two 
independent researchers blind to the treatment groups using a similar scoring system 
reported by Erboga et al.25 Randomly selected cardiac sections were imaged and assessed 
for signs of myocardial damage, namely myofibrillar loss, cytoplasmic vacuolisation, 
myocardial disorganisation, inflammatory cell infiltration and haemorrhages with a score 
of no damage (0), mild (1), moderate (2) and severe (3). 
 
Statistical analysis 
Statistical analysis was carried out using an unpaired t-test, one way ANOVA with 
Dunnett’s post hoc analysis or two-way ANOVA with Dunnett’s post hoc analysis where 
appropriate (GraphPad Prism 7 software). All graphs and values are represented as average 
values ± standard deviation (SD). Differences between datasets were deemed statistically 
significant when the observed confidence interval, P<0.05. 
 
Results 
 
In vitro analysis on Langendorff perfused hearts 
Infusion of CCCP (300 nmol/L) into isolated perfused hearts invoked a significant increase 
in LVEDP, from 6.9 ± 2.3 to 67.5 ± 10.0 mmHg, and significant decrease in LVDP from 
122.4 ±11.1 to 37.7 ± 17.1 mmHg vs control experiments, at 65 min post perfusion 
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(Supplement Figure 1). Cardiac time-activity profiles were measured from the cardiac 
orientated -detector, for both 18F-Mitophos and 99mTc-Sestamibi (Figure 2 A, B). In 
control hearts, 18F-Mitophos exhibited an average single pass extraction and retention of 
66 ± 5% (n = 5) of injected spike at 20 min post injection in comparison to 99mTc-Sestamibi 
which showed 31 ± 4% (n = 5) retention. In control hearts the kinetic washout rate, K, from 
2 min post injection for 18F-Mitophos and 99mTc-Sestamibi was 1.1x10-3 ± 3x10-4%ID/min 
and 4.5x10-3 ± 1.0x10-3%ID/min respectively (Supplement Figure 1). Upon treatment with 
CCCP both 18F-Mitophos (n = 4) and 99mTc-Sestamibi (n = 6) showed a significant decrease 
in retention from 2 min post injection which was maintained throughout (15% and 12% of 
injected dose respectively by the end of protocol) (Figure 2 A, B). A significant increase 
in K was observed for both tracers in hearts treated with CCCP (Supplement Figure 2), 
with relative increase of 469 ± 150% and 395 ± 146% for 18F-Mitophos and 99mTc-
Sestamibi respectively (Figure 2C). 
 
Ex vivo Biodistribution of 18F-Mitophos and 18F-FBnTP 
Ex vivo tissue biodistribution and image derived (30-60 min) SUV data for 18F-Mitophos 
and 18F-FBnTP are shown in Table 1. There was no substantial bone uptake, alongside 
good metabolic stability of 18F-Mitophos in vivo, with 40% of the parent compound still 
present in plasma at 60 min post injection (Supplement Table 1 and Supplement Figure 3). 
In accordance with the isolated heart experimental results, fast uptake and high retention 
of 18F-Mitophos was observed in the myocardium of healthy animals with an average SUV 
from ex vivo biodistribution of 5.40  0.61 at 5 min post injection and 5.17  0.86 at 60 min. 
Rapid clearance of 18F-Mitophos from the plasma, liver and lungs was observed, with 
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relative heart to tissue ratios at 60 min of; 303.9  136.0, 11.2  1.2 and 3.8  0.6 
respectively. Distinction of the entire myocardium from all surrounding tissues was 
apparent in PET-derived images. Intra-animal variability data of 18F-Mitophos 
(Supplement Figure 4) showed good cardiac uptake repeatability with average divergence 
of image derived cardiac SUV of 8.0  4.3% from baseline scans. 
 
18F-FBnTP showed similar biodistribution to 18F-Mitophos, with higher uptake in the heart 
(SUV 7.42  0.43 at 5 min via ex vivo biodistribution), and rapid clearance from the 
bloodstream (Table 1) High liver uptake and retention was observed, with consistent heart 
to liver ratios around 2 throughout the 60 min protocol.  
 
Acute DOX treatment model 
Progressive weight loss was observed over the 48 h period for every DOX treatment group 
with the 15 mg/kg DOX group showing greatest weight loss of 7.0  1.5%. No severe 
adverse effects, as defined by two or more persistent signs of ill health, or unscheduled 
deaths, were encountered through the acute experiment (Supplement Table 2). Ex vivo 
tissue biodistribution data supports a significant, dose dependent decrease in cardiac 
retention at 60 min post 18F-Mitophos injection in all DOX-treated groups with SUV 
decreased from 5.3  0.9 (control) to 3.4  0.3 (20 mg/kg DOX), P<0.001 (Figure 3 A). 
Strong correlation with cardiac SUV derived from the dynamic scan data (Figure 3 B, 
Figure 4) was observed, with a decrease in left ventricle cardiac SUV30-60 from 3.5  0.5 in 
control, to 1.8  0.1, P<0.001 for the 20 mg/kg DOX group. Image derived myocardial 
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TAC’s showed significant alteration between control and DOX treated groups for 
myocardium and lung (Figure 5, Supplement Figure 6). No significant alterations were 
observed in SUV of liver, kidney, blood or plasma by ex vivo biodistribution across 
treatment groups (Supplement Figure 5). 
 
Biomarker and histological assessment of in vivo DOX-induced cardiac damage 
Cardiac troponin-I levels in the plasma 48 h post DOX dose were below the limit of 
detection of the assay (39 pg/mL) for every sample in each treatment group. No significant 
differences in MDA concentration were detected in cardiac tissue collected at the end of 
the protocol across all groups (Supplement Figure 7). Histological assessment of cardiac 
damage showed substantial increase in semi-quantitative damage assessment between 
treatment groups and DOX treated groups (Table 2). Typical examples of cardiac sections 
categorised are displayed in Supplement Figure 8. 
 
Discussion 
 
The long term cardiotoxic side effects of chemotherapy treatment are becoming 
increasingly important as cancer detection and survival rates increase. The current methods 
for cardiotoxicity monitoring rely on late-stage, structural and/or mechanical cardiac 
dysfunction, where irreversible damage has already occurred, and the optimal window for 
intervention past. Research into radiolabelled tracers as potential early identifiers of 
cardiotoxicity show some potential, but tracers investigated to date have various 
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limitations. Here, we show that 18F-Mitophos has a favourable pharmacokinetic profile for 
cardiac imaging and is responsive to DOX induced cardiotoxicity in an acute rodent model. 
 
Historically, radiolabelled lipophilic cations have long been used as myocardial perfusion 
imaging agents, based on the assumption that their rapid sequestration into cardiac 
mitochondria is primarily limited by their delivery.26,27 However, more recently, the 
repurposing of the approach to report upon mitochondrial membrane potential itself is 
becoming of interest. A number of recent preclinical imaging studies have investigated the 
potential of utilising PET radiolabelled lipophilic cation tracers in myocardial infarction 
models,17,28,29 as well as for the quantification of cardiotoxicity by SPECT imaging.18 To 
directly compare the in vivo performance of 18F-Mitophos to another lipophilic cation 18F-
FBnTP was chosen as the only PET lipophilic cation agent to be translated into man. 
 
In the Langendorff perfusion heart model, the cardiac retention of 18F-Mitophos in control 
perfused hearts was over double that of 99mTc-Sestamibi, with a higher first-pass extraction 
and four times slower washout rate from 2 min post injection. This indicates that cardiac 
uptake of 18F-Mitophos in vivo will likely be higher than that of 99mTc-Sestamibi, and 
retained for longer. Both tracers exhibited significant washout in response to mitochondrial 
depolarisation with the ionophore CCCP, indicating their potential to report on 
mitochondrial dysfunction in vivo. 
 
Our in vivo pharmacokinetic and biodistribution studies confirmed high uptake and stable 
retention of both 18F-Mitophos and 18F-FBnTP in the myocardium, and efficient washout 
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from blood. 18F-Mitophos showed efficient washout from the liver with heart to liver ratios 
>11 by 60 min, whereas for 18F-FBnTP this remained at 2 throughout, in line with 
previously published studies.30 Because of the proximity of heart and liver, high hepatic 
retention can impact on a tracer’s usefulness in cardiac imaging with estimations of SUV 
in the cardiac apex becoming problematic. This is a major issue of many cardiac tracers in 
human studies, including 18F-FBnTP where ratios are substantially lower than in rodents 
(<0.2).31 As such, the rapid clearance from the liver that 18F-Mitophos displays may be a 
significant advancement over currently used agents, warranting further investigation into 
its use as a PET cardiac perfusion imaging agent. 
 
In this study, a single acute DOX dose was applied to investigate the ability of 18F-
Mitophos to image cardiac tissue damage, and is the first to characterise a PET 
radiolabelled lipophilic cation for imaging DOX-induced cardiotoxicity. 18F-Mitophos 
showed a significant, dose-dependent decrease in cardiac uptake in animals treated with 
DOX, with left ventricular retention decreasing to almost 50% of controls from dynamic 
scan data. These results were obtained before detectable plasma levels of cardiotoxicity 
biomarker cardiac troponin-I had accrued, or significant alterations in cardiac MDA 
occurred.  
 
The lack of biomarker alteration observed in this study is in line with other acute DOX 
models in the literature. Biomarker alterations are generally observed only after longer 
timeframes, 72-96 h,24,32 or with higher DOX doses, over 48 h.25,33,34 However, in our 
model histological assessment of cardiac tissue detected an increase in tissue damage. This 
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indicates that mitochondria or ΔΨm may be compromised in the early stages of 
cardiotoxicity, and that changes seen with 18F-Mitophos may allow early detection of 
cardiotoxicity. Another possibility is a reduction in blood flow due to cardiac atrophy, 
which has been shown in humans and rodents after prolonged exposure to DOX.35,36 While 
we cannot definitively rule this out as a contributor, a similar DOX study showed no 
response in perfusion tracer 99mTc-NOET, implying no alteration in perfusion, but 
observing significant decrease in 99mTc-Sestamibi (also a lipophilic cation).18 The lack of 
comparison to other perfusion tracers is, however, a limitation of the study. While the initial 
data presented here on 18F-Mitophos show promise, additional studies are required. 
Chronic models more representative of clinical procedures would allow meaningful 
comparison to echo techniques and assess clinical translation potential.   
 
In conclusion, we have reported the potential of the radiolabelled lipophilic cation PET 
tracer 18F-Mitophos for imaging evolving mitochondrial cardiotoxicity. 18F-Mitophos 
showed improved pharmacokinetic characteristics over clinically used radiolabelled 
lipophilic cations, for the purposes of cardiac imaging, with fast washout from blood and 
liver and stable retention in the myocardium. We also reported the significant dose 
response of 18F-Mitophos cardiac uptake to acute DOX dose 48 h prior. These results show 
that 18F-Mitophos is a promising agent for imaging DOX induced cardiotoxicity, with 
potential as an early diagnostic tool. Further studies on 18F-Mitophos in chronic toxicity 
models are justified from the results outlined within this work. 
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KEY POINTS 
QUESTION: Is 18F-Mitophos applicable to imaging mitochondrial dysfunction upon 
acute DOX cardiotoxicity? 
PERTINENT FINDINGS: The pharmacokinetic profile of 18F-Mitophos in rodents is 
suitable for cardiac imaging, with fast liver clearance a notable advantage over current in-
human lipophilic cation tracers. Significant and dose responsive decrease in 18F-Mitophos 
cardiac uptake was observed upon acute DOX treatment. 18F-Mitophos shows promise as 
a cardiac imaging agent and warrants further investigation into cardiotoxicity 
applications. 
IMPLICATIONS FOR PATIENT CARE: Early detection of cardiotoxicity may improve 
chemotherapy morbidity rates.  
  
by King's College London on June 3, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
 18
References 
1.  Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 
2016;66(1):7-30. 
2.  Blum RH, Carter SK. Adriamycin. Ann Intern Med. 1974;80(2):249. 
3.  Bloom MW, Hamo CE, Cardinale D, et al. Cancer Therapy–Related Cardiac 
Dysfunction and Heart Failure. Circ Hear Fail. 2016;9(1):e002761. 
4.  Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. 
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to 
therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213-1225. 
5.  Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of 
adriamycin cardiotoxicity. Cancer. 1973;32(2):302-314. 
6.  Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. 
Cardiology. 2010;115(2):155-162. 
7.  Layard MW, Basa P, Davis HL, Hoff AL Von, Rozencweig M, Muggia FM. Risk 
Factors for Doxorubicin-lnduced Congestive Heart Failure. Ann Intern Med. 
1979;91(5):710. 
8.  Cardinale D, Colombo A, Bacchiani G, et al. Early Detection of Anthracycline 
Cardiotoxicity and Improvement With Heart Failure Therapy Clinical Perspective. 
Circulation. 2015;131(22):1981-1988. 
by King's College London on June 3, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
 19
9.  Kongbundansuk S, Hundley WG. Noninvasive Imaging of Cardiovascular Injury 
Related to the Treatment of Cancer. JACC Cardiovasc Imaging. 2014;7(8):824-
838. 
10.  Jiji RS, Kramer CM, Salerno M. Non-invasive imaging and monitoring 
cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol. 2012;19(2):377-388. 
11.  Bennink RJ, van den Hoff MJ, van Hemert FJ, et al. Annexin V imaging of acute 
doxorubicin cardiotoxicity (apoptosis) in rats. J Nucl Med. 2004;45(5):842-848. 
12.  Inglese E, Leva L, Matheoud R, et al. Spatial and temporal heterogeneity of 
regional myocardial uptake in patients without heart disease under fasting 
conditions on repeated whole-body 18F-FDG PET/CT. J Nucl Med. 
2007;48(10):1662-1669. 
13.  de Geus-Oei L-F, Mavinkurve-Groothuis AMC, Bellersen L, et al. Scintigraphic 
techniques for early detection of cancer treatment-induced cardiotoxicity. J Nucl 
Med. 2011;52(4):560-571. 
14.  Olmos RAV, Bokkel Huinink WW te., Hoeve RFA te., et al. Assessment of 
anthracycline-related myocardial adrenergic derangement by 
[123i]metaiodobenzylguanidine scintigraphy. Eur J Cancer. 1995;31(1):26-31. 
15.  Damiani RM, Moura DJ, Viau CM, Caceres RA, Henriques JAP, Saffi J. 
Pathways of cardiac toxicity: comparison between chemotherapeutic drugs 
doxorubicin and mitoxantrone. Arch Toxicol. 2016;90(9):2063-2076. 
by King's College London on June 3, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
 20
16.  Renu K, V.G. A, P.B. TP, Arunachalam S. Molecular mechanism of doxorubicin-
induced cardiomyopathy – An update. Eur J Pharmacol. 2018;818:241-253. 
17.  Mou T, Zhang X. Research Progress on 18F-Labeled Agents for Imaging of 
Myocardial Perfusion with Positron Emission Tomography. Molecules. 
2017;22(4):562. 
18.  Safee ZM, Baark F, Waters ECT, et al. Detection of anthracycline-induced 
cardiotoxicity using perfusion-corrected 99mTc sestamibi SPECT. Sci Rep. 
2019;9(1):216. 
19.  Haslop A, Gee A, Plisson C, Long N. Fully automated radiosynthesis of [1-(2-
[18F]fluoroethyl),1H[1,2,3]triazole 4-ethylene] triphenylphosphonium bromide as 
a potential positron emission tomography tracer for imaging apoptosis. J Label 
Compd Radiopharm. 2013;56(6):313-316. 
20.  Haslop A, Wells L, Gee A, Plisson C, Long N. One-pot multi-tracer synthesis of 
novel (18)F-labeled PET imaging agents. Mol Pharm. 2014;11(11):3818-3822. 
21.  Ravert HT, Madar I, Dannals RF. Radiosynthesis of 3-[18F]fluoropropyl and 4-
[18F]fluorobenzyl triarylphosphonium ions. J Label Compd Radiopharm. 
2004;47(8):469-476. 
22.  Handley MG, Medina RA, Mariotti E, et al. Cardiac Hypoxia Imaging: Second-
Generation Analogues of 64Cu-ATSM. J Nucl Med. 2014;55(3):488-494. 
23.  Mariotti E, Veronese M, Dunn JT, et al. Assessing radiotracer kinetics in the 
by King's College London on June 3, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
 21
Langendorff perfused heart. EJNMMI Res. 2013;3(1):74. 
24.  Poussios D, Andreadou I, Papalois A, et al. Protective effect of a novel 
antioxidant non-steroidal anti-inflammatory agent (compound IA) on intestinal 
viability after acute mesenteric ischemia and reperfusion. Eur J Pharmacol. 
2003;465(3):275-280. 
25.  Erboga M, Bozdemir Donmez Y, Sener U, Fidanol Erboga Z, Aktas C, Kanter M. 
Effect of Urtica Dioica against Doxorubicin-Induced Cardiotoxicity in Rats 
through Suppression of Histological Damage, Oxidative Stress and Lipid 
Peroxidation. Eur J Gen Med. 2016;13(2):139-144. 
26.  Zhang X, Liu XJ, Wu Q, et al. Clinical outcome of patients with previous 
myocardial infarction and left ventricular dysfunction assessed with myocardial 
(99m)Tc-MIBI SPECT and (18)F-FDG PET. J Nucl Med. 2001;42(8):1166-1173. 
27.  DePuey, Gordon; Rozanski A. Using Gated Technetium-99m-Sestamibi SPECT 
to Characterize Fixed Myocardial Defects as Infarct or Artifact. J Nucl Med. 
1993;34(34):952-955. 
28.  Madar I, Ravert H, DiPaula A, Du Y, Dannals RF, Becker L. Assessment of 
Severity of Coronary Artery Stenosis in a Canine Model Using the PET Agent 
18F-Fluorobenzyl Triphenyl Phosphonium: Comparison with 99mTc-
Tetrofosmin. J Nucl Med. 2007;48(6):1021-1030. 
29.  Shoup TM, Elmaleh DR, Brownell A-L, Zhu A, Guerrero JL, Fischman AJ. 
by King's College London on June 3, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
 22
Evaluation of (4-[18F]Fluorophenyl)triphenylphosphonium Ion. A Potential 
Myocardial Blood Flow Agent for PET. Mol Imaging Biol. 2011;13(3):511-517. 
30.  Madar I, Ravert H, Nelkin B, et al. Characterization of membrane potential-
dependent uptake of the novel PET tracer 18F-fluorobenzyl 
triphenylphosphonium cation. Eur J Nucl Med Mol Imaging. 2007;34(12):2057-
2065. 
31.  Srinivasan S, Muhammad C, Ravert H, et al. Human biodistribution and radiation 
dosimetry of 18F-fluorobenzyltriphenyl phosphonium. J Nucl Med. 
2012;53(supplement 1):1512. 
32.  Kwatra M, Kumar V, Jangra A, et al. Ameliorative effect of naringin against 
doxorubicin-induced acute cardiac toxicity in rats. Pharm Biol. 2016;54(4):637-
647. 
33.  Goyal SN, Mahajan UB, Chandrayan G, et al. Protective effect of oleanolic acid 
on oxidative injury and cellular abnormalities in doxorubicin induced cardiac 
toxicity in rats. Am J Transl Res. 2016;8(1):60-69. 
34.  Saad SY, Najjar TA, Al-Rikabi AC. The preventive role of deferoxamine against 
acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol 
Res. 2001;43(3):211-218. 
35.  Ferreira de Souza T, Quinaglia A.C. Silva T, Osorio Costa F, et al. Anthracycline 
Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical 
by King's College London on June 3, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
 23
Manifestations of Heart Disease. JACC Cardiovasc Imaging. 2018;11(8):1045-
1055. 
36.  Willis MS, Parry TL, Brown DI, et al. Doxorubicin Exposure Causes Subacute 
Cardiac Atrophy Dependent on the Striated Muscle–Specific Ubiquitin Ligase 
MuRF1. Circ Hear Fail. 2019;12(3). 
 
 
  
  
by King's College London on June 3, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
 24
TABLE 1  
18F-FBnTP 5 15 30 60 
Blood 0.12 (0.22) 0.16 (0.06) 0.12 (0.06) 0.04 (0.01) 
Plasma 0.56 (0.51) 0.08 (0.06) 0.05 (0.04) 0.02 (0.00) 
Muscle 0.30 (0.12) 0.22 (0.12) 0.21 (0.04) 0.34 (0.14) 
Spleen 5.63 (0.28) 4.58 (1.22) 3.17 (1.65) 2.49 (0.76) 
Liver 3.71 (0.93) 3.57 (0.65) 3.58 (1.06) 3.59 (0.73) 
Adrenals 6.87 (9.16) 9.84 (1.74) 11.33 (5.33) 7.00 (2.49) 
Kidney 17.57 (5.27) 30.08 (3.81) 32.24 (3.44) 25.81 (5.92) 
Lung 2.09 (0.38) 2.03 (0.12) 2.09 (0.27) 1.63 (0.47) 
Heart 7.42 (0.43) 7.32 (0.69) 7.93 (2.45) 6.75 (1.54) 
Brain 0.07 (0.03) 0.05 (0.01) 0.06 (0.02) 0.03 (0.01) 
Heart/Plasma 13.2 (12.0) 95.6 (70.9) 153.1 (135.2) 422.7 (142.5) 
Heart/Lung 3.6 (0.7) 3.6 (0.4) 3.8 (1.3) 4.1 (1.5) 
Heart/Liver 2.0 (0.5) 2.1 (0.4) 2.2 (0.9) 1.9 (0.6) 
18F-Mitophos 5 15 30 60 
Blood 0.35 (0.17) 0.16 (0.02) 0.14 (0.02) 0.06 (0.02) 
Plasma 0.19 (0.11) 0.06 (0.01) 0.07 (0.02) 0.02 (0.01) 
Muscle 0.30 (0.04) 0.22 (0.02) 0.24 (0.06) 0.22 (0.06) 
Spleen 6.67 (1.87) 6.04 (0.36) 7.28 (0.55) 4.231 (0.83) 
Liver 3.91 (0.69) 2.25 (0.30) 1.53 (0.30) 0.463 (0.12) 
Adrenals 12.50 (4.52) 11.32 (1.31) 21.16 (6.47) 14.30 (4.25) 
Kidney 20.77 (1.63) 17.76 (0.28) 21.69 (1.37) 18.64 (4.57) 
Lung 2.36 (0.15) 2.97 (1.42) 1.43 (0.25) 1.37 (0.36) 
Heart 5.40 (0.61) 4.60 (0.32) 5.17 (0.56) 5.17 (0.86) 
Brain 0.08 (0.01) 0.07 (0.00) 0.06 (0.01) 0.05 (0.01) 
Heart /Plasma 28.3 (16.6) 82.2 (15.7) 95.7 (36.9) 303.9 (185.8) 
Heart /Lung 2.3 (0.3) 1.6 (0.7) 3.6 (0.7) 3.8 (0.6) 
Heart /Liver 1.4 (0.5) 2.0 (0.2) 3.4 (0.8) 11.2 (1.2) 
Selected ex vivo biodistribution data for 18F-FBnTP and 18F-Mitophos and heart to tissue 
ratios for selected tissues. All values are reported as average SUV (SD) determined by 
gamma counter measurement for each timepoint/ min. 
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TABLE 2  
 Assessor 1 Assessor 2 
Dose Average median Range Average median Range 
Control 0 0-1 0.5 0-2 
10 mg/kg 2 0-3 2.5 0-3 
15 mg/kg 2.5 1-3 2.75 2-3 
20 mg/kg 2.25 1-3 2.5 1-3 
Histological assessment of H&E stained tissue sections of control and DOX treated 
myocardium. Each section was scored with severity rating of 0 (NAD), 1 (mild signs of 
damage), 2 (moderate), or 3 (severe). The average median donates the median score of 
each heart (n = 3 sections) averaged over the treatment group. The range denotes the total 
range of sections within a treatment group. 
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FIGURE 1. Radiosynthetic pathway for PET tracers. A) 18F-FBnTP B) 18F-Mitophos. 
TBTA is tris(benzyltriazolylmethyl)amine, RT is room temperature and NaC6H7O6 is 
sodium ascorbate.  
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FIGURE 2. Cardiac retention of percentage injected dose of A) 18F-Mitophos and B) 
99mTc- Sestamibi in Langendorff perfused hearts in control and CCCP (300 nM) treated. 
C) Relative increase in washout rate, K, (CCCP treated/control) hearts for 18F-Mitophos 
and 99mTc-Sestamibi. (Statistical analysis was two-way ANOVA and Dunnett’s post hoc 
analysis (A, B) and two tailed t-test (C). * P< 0.05, ** P< 0.01, *** P< 0.001).  
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FIGURE 3. Uptake of 18F-Mitophos in control and DOX treated animals (mean ± SD). A) 
Ex vivo biodistribution of collected cardiac tissue (60 min p.i.). B) Average SUV30-60 from 
left ventricle, lung and liver TAC, derived from dynamic PET-CT scan. (Statistical analysis 
was one-way ANOVA and Dunnett’s post hoc analysis. * P<0.05, *** P<0.001).  
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FIGURE 4. Representative axial, sagittal and coronal co-registered PET-CT image 
(summed from 30 to 60 min) 18F-Mitophos in Sprague Dawley rats 48 h post DOX dose. 
Control (top), 15 mg/kg (middle) and 20 mg/kg (bottom). The left and right ventricles are 
highlighted with LV and RV respectively.  
LV 
RV 
LV 
RV 
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FIGURE 5. TACs (average SUV ± SD) of 18F-Mitophos in Sprague Dawley rats for the 
left ventricle. SUV’s are displayed over the duration of the scan (A) and for the first minute 
(B). Significant decrease in cardiac uptake for both the 15 mg/kg and 20 mg/kg dose in the 
myocardium is observed. Statistical analysis two-way ANOVA and Dunnett’s post hoc 
analysis. *** P<0.001 for control compared to DOX 20 mg/kg, †† P<0.01 for control 
compared to DOX 15 mg/kg *, ** and † confidence intervals were omitted for clarity in A) 
and occurred only prior indicated regions.  
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Mitophos  
 
Methods and Materials  
 
Radiochemistry Procedures 
Production of 18F-FBnTP 
To 18F-fluoride, azeotropically dried in the presence of Kryptofix and K2CO3, 4-
trimethylammoniumbenzaldehyde (10 mg) in dimethylformamide (DMF, 400 μL) was added, and heated 
to 110 °C for 10 min. Sodium borohydrate (15 mg) in H2O (500 μL) was added to the cooled reaction 
vessel and reacted at room temperature for 5 min. Conc. hydroiodic acid (1 mL) was added to the same 
reaction vial and reacted for 10 min. The reaction mixture was diluted with H2O and passed through a C-
18 cartridge. The cartridge was washed with sodium thiosulphate/K2CO3 solution and water before 
elution with ACN through molecular sieves and a sodium sulphate drying cartridge, into a vial containing 
triphenyl phosphine (21 mg) in ACN (Figure. 1). The sealed vial was heated to 110 °C for 10 min before 
being allowed to cool to room temperature. 18F-FBnTP was then purified by HPLC and reformulated in 10 
% ethanol, saline solution. Purity was confirmed by analytical radio-HPLC. Specific activity 15.0 ± 12.6 
GBq/μmol. 
 
Production of 18F-Mitophos 
Tosyl ethyl azide in acetonitrile (ACN) was added to 18F-fluoride, azeotropically dried in the presence of 
Kryptofix and K2CO3, and heated for 5 min at 105 °C. 18F-Fluoroethyl azide was distilled into a vial 
containing CuSO4·5H2O (56 μL, 0.4 mmol/L), tris(benzyltriazolylmethyl)amine (TBTA) (1 mg), sodium 
ascorbate (40 mg) 3-but-3-ynyl (tris-3,5-dimethylphenyl)phosphonium bromide (2 mg) in H2O:EtOH 3:1 
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solution. The reaction was left for 5 min after distillation had completed and reaction mixture purified 
by isocratic high performance liquid chromatography (HPLC) (ACN: ammonium formate buffer, pH 4 
100 mmol/L, 50:50) (Figure. 1). 18F-Mitophos was reformulated in 10 % EtOH and saline and purity 
confirmed by analytical radio-HPLC. Specific activity 24.6 ± 18.3 GBq/μmol. 
 
Animal Procedures 
Animal husbandry 
Animals were group-housed within individually ventilated cages with Aspen grade 6 bedding under a 
12/12 light dark cycle (lights on 7am, off 7pm) at set temperature and humidity ranges of 19-23 °C and 
45-65 % respectively. Food and water were available ad libitum and environmental enrichment was 
provided. 
 
Langendorff Heart Perfusion 
After intraperitoneal injection of pentobarbital, hearts were excised from male Wistar rats and 
cannulated onto a Langendorff perfusion rig. Hearts were perfused with modified Krebs-Henseleit buffer 
(37°C gassed with 95 % O2/ 5 % CO2) at a constant flow rate of 14 mL/min. Cardiac tracer retention and 
washout was monitored throughout each experiment using GinaSTAR software via the triple 𝛾-detection 
system, while cardiac contractile function was monitored with an intraventricular balloon connected to 
a Powerlab system running Labchart software (AD Instruments Ltd). After a stabilisation period of 
20 min, CCCP (at a final concentration of 300 nmol/L) or vehicle was infused into the aortic cannula via a 
side arm. After 25 min, a bolus of radiotracer (approximately 1 MBq, 50-100 µl) was injected into the 
arterial line. 
 
In vivo procedures 
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All in vivo and procedures were carried out under anaesthesia (2-3 % isoflurane in air 1 L/min) and 
animal body temperature maintained by heating mats, with rectal probe feedback. For dynamic PET:CT 
cardiac scanning, animals were placed within the central bore of a Siemens Inveon PET-CT scanner with 
the field of view over the heart. A CT scan was conducted for attenuation correction before injection of 
radiotracer and dynamic PET data acquired (60 min). Radiopharmaceuticals were administered via direct 
venepuncture of the tail vein. At the end of the protocol animals were culled via exsanguination under 
deep anaesthesia (4 % isoflurane, air 1L/min) and tissues were collected in ice-cold saline, weighed and 
radioactivity measured via gamma counter (Wizard). Dynamic scan data was histogrammed (frames, sec; 
10, 3; 6, 5; 8, 30; 5, 60; 6, 300; 2, 600) and reconstructed (2D-filter back projection). One animal within 
the DOX study was excluded due to a failed IV injection and was part of the 10 mg/kg group, this data 
point was not replaced. 
 
Ex vivo analysis  
Metabolite quantification 
Blood samples were periodically collected (5, 10, 20, 40 and 60 min, n=3 per timepoint). Proteins were 
precipitated from plasma with acetonitrile (ACN) (1:1) and centrifugation at 12000 x g for 5 min 90 % 
ACN: 10 % 50 mM ammonium formate, pH 4, 5 mL/min, was used as the mobile phase with a 
Phenomenex Prodigy semi-preparative column ODS(3), (10 micron, 250 x 10 mm) column. Typical 
activity recovery from HPLC was >90 %. 
 
Malondialdehyde (MDA) quantification  
Left ventricle tissue from the apex of the heart was homogenised in ice cold 20 mM Tris-HCL buffer pH 
7.4 in a 1:10 ratio before briefly sonicating samples. Homogenate was centrifuged at 3000 x g for 10 min 
at 4 C and the supernatant removed for analysis 200 L of tissue homogenate was added to 650 L of 
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10.3 mmol/L N-methyl-2-phenyl-indole in ACN and vortexed for 3-4 s. 150 L of HCL 37 % was added 
and samples incubated at 45 C for 60 min. The samples were cooled in ice and centrifuged before 3 x 
200 L aliquots per sample were transferred to a 96 well plate for reading (absorbance, 586 nm). A 
standard curve from 1.25 to 40 nmol/mL MDA was used for quantification (R2 >0.999). 
 
 
SUPPLEMENT TABLE. 1. Dosimetry data for 18F-Mitphos calculated from Sprague Dawley rats (n=3 per 
timepoint at 5, 15, 30 and 60 min). 
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Clinical sign 10 mg/kg 15 mg/ kg 20 mg/kg 
Piloerection 3/6 5/6 6/6 
Hunched posture 1/6 1/6 2/6 
Vocalisation 0/6 1/6 0/6 
Average BW loss/ % 5.3 ± 2.8 7.0 ± 1.5 6.5 ± 2.4 
 
SUPPLEMENT TABLE. 2. Adverse effects signs observed for DOX infused animals over the 48 h period 
post dose.  Animals were assessed twice daily and weighed daily. Weight loss is quoted as the total 
weight loss over the 48 h period. 
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SUPPLEMENT FIGURE. 1. Cardiac parameters for hearts perfused on the Langendorff perfusion rig. 
Significant response to both A) LVEDP and B) LVDP are observed upon treatment with CCCP 300 nM 
from 20 min until the end of protocol showing decreased function of the perfused heart upon CCCP 
infusion. Data prior to 20 min represents manual perfusion of the heart and stabilisitation period and is 
therefore excluded. Statistical analysis was 2-way ANOVA and Dunnett’s post hoc analysis. *** P<0.001. 
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 SUPPLEMENT FIGURE. 2. Washout rate, K, in the Langendorff perfused heart model. K is the least square 
fit of the exponential washout rate between 2 min post injection and 20 min post injection for A) 18F-
Mitophos and B) 99mTc-Sestamibi. Statistical analysis was 1-tailed student t-test, *** P<0.001. 
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 SUPPLEMENT FIGURE. 3. Metabolism profile of 18F-Mitophos in Sprague Dawley rats (n=2). Plasma was 
extracted from blood samples and compared to metabolite concentrations via HPLC chromatogram. >90 
% activity was recovered from HPLC. 
 
  
by King's College London on June 3, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
   
SUPPLEMENT FIGURE. 4. Test-retest data of 18F-Mitophos uptake in cardiac tissue at 60 min in Sprague 
Dawley rats. Ratio of left ventricle SUV30-60 derived from dynamic scan TAC’s (retest/baseline) from two 
scans 48-72 h apart was used.  
  
0.0
0.5
1.0
1.5
by King's College London on June 3, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
  
SUPPLEMENT FIGURE. 5. Cut and count activity at 60 min p.i. of 18F-Mitophos in blood (A), plasma (B), 
Liver (C) and kidney (D) from control and DOX treated rats. No significant alteration was observed in any 
tissue group. 
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SUPPLEMENT FIGURE. 6. Time activity curves (average SUV ± SD) of 18F-Mitophos in Sprague Dawley rats 
from A) liver, B) lung, C) blood pool and D) blood pool from the first minute. *** P<0.001 for control 
compared to DOX 20 mg/kg, †† P<0.01 for control compared to DOX 15 mg/kg *, ** and † confidence 
intervals were omitted for clarity in A) and occurred only directly adjacent to indicated regions. Blood 
pool TAC after approximately 1 min must be treated with extreme caution as, due to the proximity and 
SUV differences to the myocardium, large partial volume effect is observed.  
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SUPPLEMENT FIGURE. 7. MDA levels measured in the apex of the cardiac tissue from control and DOX 
treated groups.  
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SUPPLEMENT FIGURE. 8. Example H&E stained longitudinal left ventricle sections (10 µm). A) control 
tissue, B) moderate damage, C) severe damage. Sections were assessed for myofibrillar loss, cytoplasmic 
vacuolisation, myocardial disorganisation, inflammatory cell infiltration and haemorrhages. 
A) B) 
C) 
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